An engineered factor Va prevents bleeding induced by direct-acting oral anticoagulants by different mechanisms

Control of bleeding with direct-acting oral anticoagulants (DOACs) remains an unmet clinical need. Activated (super)Factor V ((super)FVa) is an engineered activated protein C (APC)–resistant FVa variant with enhanced procoagulant activity resulting from an A2/A3 domain disulfide bond and was studied...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Blood Adv
Main Authors: von Drygalski, Annette, Bhat, Vikas, Gale, Andrew J., Averell, Patricia M., Cramer, Thomas J., Elias, Darlene J., Griffin, John H., Mosnier, Laurent O.
Formato: Artigo
Idioma:Inglês
Publicado: American Society of Hematology 2020
Assuntos:
Thrombosis and Hemostasis
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC7422119/
https://ncbi.nlm.nih.gov/pubmed/32777068
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/bloodadvances.2020001699
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares